Physician profile
Matthew E Woodske
NPI 1114957990
$3,003.35
in general payments reported to CMS, 2019-2025
34 companies · $77.95 in 2025
The $77.95 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $208 · 2021: $420 · 2022: $405 · 2023: $558 · 2024: $515 · 2025: $77.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,117 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,117.29 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $572.95 | 2019-2024 | Trelegy Ellipta, Nucala |
| Ethicon INC. | $440.61 | 2021-2025 | Monarch Platform |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.90 | 2019-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals Lp | $232.82 | 2019-2024 | Tezspire, Airsupra |
| Insmed, INC. | $139.12 | 2019-2024 | Arikayce |
| Novartis Pharmaceuticals Corporation | $138.28 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $117.56 | 2019-2023 | Dupixent |
| Amgen INC. | $117.16 | 2022-2025 | Tezspire |
| Genzyme Corporation | $98.63 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $87.16 | 2022-2023 | |
| Philips North America LLC | $77.09 | 2022-2024 | (Ak6) Vest Therapy |
| Genentech USA, INC. | $69.92 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $63.59 | 2019 | |
| Janssen Pharmaceuticals, INC | $58.59 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $56.92 | 2023-2024 | Opsumit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $51.06 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $38.33 | 2020-2024 | Nuzyra |
| Shire North American Group INC | $35.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.69 | 2023 | Glassia |
| Baxter Healthcare | $30.63 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Inspire Medical Systems, INC. | $30.01 | 2023-2024 | Inspire |
| Ambu INC. | $27.77 | 2024 | |
| Grifols USA, LLC | $23.85 | 2023 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $18.48 | 2019 | |
| Mallinckrodt Enterprises LLC | $16.69 | 2019 | |
| Advanced Respiratory, INC | $16.60 | 2020 | |
| Circassia INC. | $15.95 | 2019 | |
| Csl Behring | $14.64 | 2020 | |
| Allergan, INC. | $14.30 | 2020 | |
| Gilead Sciences, INC. | $14.05 | 2019 | |
| Biomerieux INC | $14.04 | 2019 | |
| Nabriva Therapeutics, Plc | $13.16 | 2020 | |
| Fisher & Paykel Healthcare INC | $13.09 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Woodske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.